Generated by AI
Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company focused on developing cancer therapeutics that address immune suppression and drug resistance. The company’s current portfolio centers on oncology candidates such as antibodies and small molecules designed to support immune function and target difficult-to-treat cancers, including prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma Ltd. also works on immunotherapy and cell therapy approaches, reflecting its emphasis on mechanisms that may help improve treatment response in cancer patients. Based in Los Angeles, California, the company operates in the biotechnology and pharmaceuticals sector, where it contributes to the development of experimental treatments intended for use in specialized oncology settings.
Website2355 Westwood Blvd.
Los Angeles, CA, 90064
United States
The latest articles about KAPA.
Kairos Pharma evaluates ENV-105 with apalutamide in a Phase 2 trial targeting drug-resistant metastatic prostate cancer patients.
Summary of Oct 8's posts. Generated by AI.
Summary of Oct 8's posts. Generated by AI.
Summary of Oct 8's posts. Generated by AI.
Investors talking about KAPA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.